Vigil Neuroscience’s (VIGL) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note released on Tuesday morning,Benzinga reports. They currently have a $22.00 price objective on the stock.

Other analysts have also issued research reports about the stock. Guggenheim lowered their target price on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Wedbush boosted their target price on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Vigil Neuroscience currently has an average rating of “Moderate Buy” and a consensus target price of $16.60.

Vigil Neuroscience Trading Up 4.5 %

Shares of NASDAQ:VIGL opened at $2.30 on Tuesday. The company has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $3.64. The firm has a market cap of $94.02 million, a PE ratio of -1.12 and a beta of 1.92. Vigil Neuroscience has a 12-month low of $2.08 and a 12-month high of $6.06.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors have recently modified their holdings of the company. Ensign Peak Advisors Inc grew its position in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares during the last quarter. abrdn plc bought a new position in shares of Vigil Neuroscience during the third quarter worth about $799,000. Point72 Asset Management L.P. bought a new position in shares of Vigil Neuroscience during the second quarter worth about $5,940,000. Vanguard Group Inc. grew its position in shares of Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vigil Neuroscience during the second quarter worth about $87,000. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.